Stockreport

Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 [Yahoo! Finance]

Tenaya Therapeutics, Inc.  (TNYA) 
PDF on Tenaya Therapeutics to $2 from $5 and kept an Overweight rating on the shares. In a sector outlook note, the firm predicted that the US small-to-mid cap biotech stock [Read more]